Antimicrobial therapeutics are medicinal products including antibiotics, antivirals, antifungals, and antiparasitics that are used to treat and prevent microbial infections. Antimicrobial therapeutics play a pivotal role in the management of various infectious diseases by either killing pathogens or suppressing their growth. The global antimicrobial resistance poses a serious threat to public health and the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, viruses, fungi, and parasites has become crucial, fueling investments in antimicrobial R&D.

The global Antimicrobial Therapeutics Market is estimated to be valued at US$155.5 billion in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/antimicrobial-therapeutics-market-5845

Market key trends:

One of the major trends witnessed in the antimicrobial therapeutics market is the rising incidence of antimicrobial resistance (AMR). The overuse and inappropriate use of existing antimicrobials has accelerated the emergence of drug-resistant pathogens. According to the WHO, at least 1.27 million people globally get infected by antimicrobial-resistant diseases each year, resulting in around 50,000 deaths. This has created an urgent need to develop novel antibiotics and therapeutics to treat drug-resistant microbial infections. Moreover, to battle AMR, governments and international organizations are promoting prudent use of antimicrobial drugs along with support for R&D initiatives. Other key trends include rising prevalence of infectious diseases, growing elderly population, strong pipeline with promising late-stage candidates, and availability of treatment guidelines and reimbursement policies shaping the market.

Porter’s Analysis

Threat of new entrants: The threat of new entrants is moderate. Developing new antimicrobial drugs require huge R&D investment and time to enter the market. The intellectual property rights and regulations also poses barrier for new players.

Bargaining power of buyers: The bargaining power of buyers is high. The buyers have large volumes and can negotiate better prices. The availability of generic alternatives provide options to buyers.

Bargaining power of suppliers: The bargaining power of suppliers is moderate. The key raw materials suppliers have some pricing power but changing suppliers is also possible for manufacturers.

Threat of new substitutes: The threat of new substitutes is high. Alternatives like antibiotics, biologics are substitute options for certain therapies. Development of resistant bacteria also raises need for novel alternatives.

Competitive rivalry: The competition in the market is high with presence of many global and regional players. Players compete on pricing, product differentiation and portfolio expansion.

Key Takeaways

The global antimicrobial therapeutics market is expected to witness high growth. The global Antimicrobial Therapeutics Market is estimated to be valued at US$155.5 billion in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.

Regional analysis: North America accounts for majority share of the global market attributed to presence of advanced healthcare infrastructure and rising funding for R&D activities. Asia Pacific exhibits lucrative opportunities owing to increasing healthcare spending, prevalence of infections and rising awareness.

Key players: Key players operating in the antimicrobial therapeutics market are Allecra Therapeutics , Melinta Therapeutics, Nabriva Therapeutics, Tetraphase Pharmaceuticals , SCYNEXIS, Alaxia . Players compete on pricing, product differentiation and portfolio expansion strategies.